Cargando…

Vedolizumab and early postoperative complications in nonintestinal surgery: a case-matched analysis

BACKGROUND: Vedolizumab (VDZ) is a gut-specific α4-β7 integrin antagonist that has demonstrated efficacy in Crohn’s disease (CD) and ulcerative colitis (UC). The safety of VDZ in the perioperative period remains unclear. The aim of this study was to evaluate postoperative complications and periopera...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kotze, Paulo Gustavo, Ma, Christopher, Mckenna, Nicholas, Almutairdi, Abdulelah, Kaplan, Gilaad G., Raffals, Laura E., Loftus, Edward V., Panaccione, Remo, Lightner, Amy L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2018
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6024272/ https://www.ncbi.nlm.nih.gov/pubmed/29977340 http://dx.doi.org/10.1177/1756284818783614

Ejemplares similares

Clinical utility of ustekinumab in Crohn’s disease
por: Kotze, Paulo Gustavo, et al.
Publicado: (2018)

Are nonintestinal inflammatory diseases and celiac disease linked?: Nonintestinal inflammatory and celiac disease
por: Bergamaschi, Roberto
Publicado: (2011)

Risk of postoperative complications among ulcerative colitis patients treated preoperatively with vedolizumab: a matched case-control study
por: Kim, Jeong Yeon, et al.
Publicado: (2020)

The old versus the new: which do you keep in postoperative Crohn's disease?
por: Kotze, Paulo Gustavo, et al.
Publicado: (2018)

The safety of vedolizumab for ulcerative colitis and Crohn's disease
por: Colombel, Jean-Frédéric, et al.
Publicado: (2017)

Long‐term safety of vedolizumab for inflammatory bowel disease
por: Loftus, Edward V., et al.
Publicado: (2020)

Cross-Sectional Analysis of Overall Dietary Intake and Mediterranean Dietary Pattern in Patients with Crohn’s Disease
por: Taylor, Lorian, et al.
Publicado: (2018)

Postoperative complications following colectomy for ulcerative colitis: A validation study
por: Ma, Christopher, et al.
Publicado: (2012)

Preoperative use of anti-tumor necrosis factor therapy in Crohn's disease: promises and pitfalls
por: Kotze, Paulo Gustavo, et al.
Publicado: (2017)

Preoperative Ustekinumab Treatment Is Not Associated With Increased Postoperative Complications in Crohn’s Disease: A Canadian Multi-Centre Observational Cohort Study
por: Shim, Hang Hock, et al.
Publicado: (2018)

Differential Expression of E-Cadherin, β-Catenin, and S100A4 in Intestinal Type and Nonintestinal Type Ampulla of Vater Cancers
por: Sung, Rohyun, et al.
Publicado: (2014)

The Argument Against a Biosimilar Switch Policy for Infliximab in Patients with Inflammatory Bowel Disease Living in Alberta
por: Kaplan, Gilaad G, et al.
Publicado: (2020)

Fr099 HEALTHCARE PROVIDER SATISFACTION WITH VIRTUAL CARE DELIVERY IN ALBERTA DURING THE COVID-19 PANDEMIC.
por: Olayinka, Lily, et al.
Publicado: (2021)

Deep Remission With Vedolizumab in Patients With Moderately to Severely Active Ulcerative Colitis: A GEMINI 1 post hoc Analysis
por: Sandborn, William J, et al.
Publicado: (2019)

Mesenchymal Stem Cells for Perianal Crohn’s Disease
por: Carvello, Michele, et al.
Publicado: (2019)

Fr098 IMPACT OF COVID-19 PANDEMIC IN IBD PATIENT CARE
por: Dahiya, Monica, et al.
Publicado: (2021)

The Impact of the COVID-19 Pandemic on IBD Care in Alberta: Patient and Provider Perspectives
por: Dahiya, Monica, et al.
Publicado: (2022)

Measuring Serum Vedolizumab and Vedolizumab Antibodies: Comparison of Commercial Assays with the Vedolizumab Clinical Development Assay
por: Vande Casteele, Niels, et al.
Publicado: (2023)

Smoking influences the need for surgery in patients with the inflammatory bowel diseases: a systematic review and meta-analysis incorporating disease duration
por: Kuenzig, M. Ellen, et al.
Publicado: (2016)

Temporal trends in the epidemiology of inflammatory bowel diseases in the public healthcare system in Brazil: A large population-based study
por: Quaresma, Abel B., et al.
Publicado: (2022)

Emerging Therapies for Ulcerative Colitis: Updates from Recent Clinical Trials
por: AlAmeel, Turki, et al.
Publicado: (2023)

The Inflammatory Bowel Diseases and Ambient Air Pollution: A Novel Association
por: Kaplan, Gilaad G, et al.
Publicado: (2010)

Quantitative Metabolomic Profiling of Serum, Plasma, and Urine by (1)H NMR Spectroscopy Discriminates between Patients with Inflammatory Bowel Disease and Healthy Individuals
por: Schicho, Rudolf, et al.
Publicado: (2012)

Point of Care Ultrasound Accurately Distinguishes Inflammatory from Noninflammatory Disease in Patients Presenting with Abdominal Pain and Diarrhea
por: Novak, Kerri L., et al.
Publicado: (2016)

The Early Experience With Vedolizumab in the United States
por: Kochar, Bharati, et al.
Publicado: (2019)

Systematic review with meta-analysis: real-world effectiveness and safety of vedolizumab in patients with inflammatory bowel disease
por: Schreiber, Stefan, et al.
Publicado: (2018)

Cost-Effectiveness of Tight Control for Crohn’s Disease With Adalimumab-Based Treatment: Economic Evaluation of the CALM Trial From a Canadian Perspective
por: Lakatos, Peter L, et al.
Publicado: (2022)

AF.51 VEDOLIZUMAB MAY BE AN EFFECTIVE OPTION FOR THE MANAGEMENT OF POSTOPERATIVE RECURRENCE OF CROHN’S DISEASE
por: Macaluso, F.S., et al.
Publicado: (2021)

Prophylactic Treatment with Vedolizumab in the Prevention of Postoperative Recurrence (POR) in High-Risk Crohn’s Patients
por: Frieri, Giuseppe, et al.
Publicado: (2023)

Vedolizumab-Associated Hypereosinophilia and Hepatoxicity
por: De Marco, Davide, et al.
Publicado: (2022)

Endoscopic Postoperative Recurrence Rates in Crohn's Disease in Korea: The Beginning of a New Approach?
por: Kotze, Paulo Gustavo, et al.
Publicado: (2014)

Smoking Is Associated with an Increased Risk for Surgery in Diverticulitis: A Case Control Study
por: Diamant, Michael J., et al.
Publicado: (2016)

Patient preferences for maintenance therapy in Crohn’s disease: A discrete-choice experiment
por: Hazlewood, Glen S., et al.
Publicado: (2020)

Parenteral Nutrition and Lipids
por: Raman, Maitreyi, et al.
Publicado: (2017)

Risk of Developing Additional Immune-Mediated Manifestations: A Retrospective Matched Cohort Study
por: Aletaha, Daniel, et al.
Publicado: (2019)

Efficacy and safety of vedolizumab in elderly patients with inflammatory bowel disease: a matched case–control study
por: Shashi, Preeti, et al.
Publicado: (2019)

Long Time from Diagnosis to Surgery May Increase Postoperative Complication Rates in Elective CD Intestinal Resections: An Observational Study
por: Kotze, Paulo Gustavo, et al.
Publicado: (2018)

Correction: Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium
por: Narula, Neeraj, et al.
Publicado: (2019)

Vedolizumab in the treatment of Crohn’s disease of the pouch
por: Khan, Freeha, et al.
Publicado: (2018)

Vedolizumab for chronic antibiotic-refractory pouchitis
por: Singh, Amandeep, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_2qn248t4lui5pp676sbp1vkue2